Very gratifying to see this work published, was a really fun team to work with and I learned a lot from all.
biorxiv.org/content/10.1101/…
Keith Graham retweeted
Our Next #MedChemCASES is coming !! and it s a joint event with the @YoungSciNet . The webinar will be followed by a round table discussing the life as foreign scientist in Germany !! Register here : us06web.zoom.us/webinar/regi…
#webinar #medchem #research
First day of my new adventure at Boehringer-Ingelheim completed! Strange to start a new job remotely, was interesting! Looking forward to learning loads and meeting new colleagues!
15
After 17 years on campus, today is my last day - very strange feeling!! Will miss a lot of friends and colleagues! Would like to thank Nuvisan ICB, Bayer and Schering for believing in me!! New adventure starts Jan 2021!
Keith Graham retweeted
First disclosure !!!!! Do you want to learn more about our AhR antagonist currently in Phase 1 ? Check Norbert’s talk next week at the virtual EFMC Program : efmc-ismc-virtual.org/speake… #NuvisanICB @EuroMedChem @BayerPharma #immunooncology
Keith Graham retweeted
After careful consideration for the safety of our members, the local community and our staff, ACS has decided to terminate the ACS Spring 2020 National Meeting in Philadelphia (#ACSPhilly). Please visit the meeting web page for complete details: ow.ly/FrEr50yH15p
Proud to have been part of a great team effort!
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction pnas.org/content/early/2019/…
1
Keith Graham retweeted
RAS genes are major oncogenes but have generally been considered undruggable. Check out our latest paper: A dual approach (FBS+HTS) supported by x-ray and biophysics generated selective nM compounds for SOS1 (activator of RAS). lnkd.in/eTcZGPt
Keith Graham retweeted
Targeting Ras, the nemesis of cancer drug discovery. A new paper by my colleagues @BayerPharma is showcasing the beauty of lead design: Hybridizing a hit from a fragment screen with a HTS lead series gives the potent probe BAY-293: @EvotecAG @PNASNews pnas.org/content/early/2019/…
Keith Graham retweeted
Happy to announce our paper on the potent and highly selective in vitro probe BAY-885 for the kinase ERK5 has been just accepted pubs.acs.org/doi/abs/10.1021…
















